Shemrock Drugs & Chemicals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 24-12-2024
- Paid Up Capital ₹ 8.32 M
as on 24-12-2024
- Company Age 16 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 Cr
as on 24-12-2024
- Revenue -58.95%
(FY 2022)
- Profit -71.49%
(FY 2022)
- Ebitda 28.72%
(FY 2022)
- Net Worth 0.09%
(FY 2022)
- Total Assets 0.52%
(FY 2022)
About Shemrock Drugs & Chemicals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 8.32 M.
The company currently has active open charges totaling ₹1.00 Cr.
Arjun Babuta, Sargun Babuta, and Om Parkash serve as directors at the Company.
- CIN/LLPIN
U24233CH2008PTC031403
- Company No.
031403
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Oct 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Shemrock Drugs & Chemicals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arjun Babuta  | Director | 19-Aug-2024 | Current |
| Sargun Babuta | Director | 01-Feb-2011 | Current |
| Om Parkash | Director | 06-Jun-2009 | Current |
Financial Performance of Shemrock Drugs & Chemicals.
Shemrock Drugs & Chemicals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 58.95% decrease. The company also saw a substantial fall in profitability, with a 71.49% decrease in profit. The company's net worth moved up by a moderate rise of 0.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shemrock Drugs & Chemicals?
In 2021, Shemrock Drugs & Chemicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Tev Consultancy Services Private LimitedActive 16 years 10 monthsArjun Babuta and Om Parkash are mutual person
- Suas Educational FoundationActive 16 years 8 months
Arjun Babuta and Sargun Babuta are mutual person
- Suas International Private LimitedActive 33 years 2 months
Sargun Babuta and Om Parkash are mutual person
Charges (Loans)
₹1.00 Cr
₹0
Charges Breakdown by Lending Institutions
- Allahabad Bank : 1.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Jun 2009 | Allahabad Bank | ₹1.00 Cr | Open |
How Many Employees Work at Shemrock Drugs & Chemicals?
Unlock and access historical data on people associated with Shemrock Drugs & Chemicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shemrock Drugs & Chemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shemrock Drugs & Chemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
